5-(thiazol-2-yl)picolinic acid | 1174322-64-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(thiazol-2-yl)picolinic acid
• 英文别名: 5-thiazol-2-yl-pyridine-2-carboxylic acid；5-(Thiazol-2-yl)pyridine-2-carboxylic acid；5-(1,3-thiazol-2-yl)pyridine-2-carboxylic acid
• CAS: 1174322-64-5
• 化学式: C₉H₆N₂O₂S
• 分子量: 206.225
• InChiKey: WYXFCAVXHLKGLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(thiazol-2-yl)picolinic acid 、 N-Boc-1,2-亚苯基二胺 在 N-(4,6-dimethoxy-1,3,5-triazin-2-yl)-N-methylmorpholinium Cl 作用下， 以 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors

  摘要：

  A lead benzamide, 3, was identified as a potent and low molecular weight histone deacetylase ( HDAC) inhibitor. Optimization led to 16d, demonstrating an excellent balance of efficacy and non-efficacy properties, along with very desirable in vivo DMPK. The final compounds presented are > 1000-fold more potent than the initial screen hit, an improvement in potency which was achieved with a concomitant significant improvement in all the main non-efficacy properties. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.041
• 作为产物：
  描述：

  methyl 5-(thiazol-2-yl)picolinate 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 以69%的产率得到5-(thiazol-2-yl)picolinic acid
  参考文献：
  名称：

  富马酸和类似物作为革兰氏阴性菌群体感应抑制剂

  摘要：

  据报道，利用微波辅助合成，高效而快捷的程序可用于制备岩藻酸和39种类似物。在基于细胞的筛选试验中测试了岩藻酸类似物对铜绿假单胞菌的las和rhl群体感应系统和费氏弧菌的lux群体感应系统的抑制作用。文库中的40种化合物中有8种（包括富马酸）抑制了lux quorum感应，而一种化合物抑制了las quorum感应系统的活性。令我们高兴的是，在所测试的浓度范围内，没有一种化合物显示出生长抑制作用。

  DOI：

  10.1016/j.ejmech.2016.11.044

文献信息

• [EN] 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS<br/>[FR] 1,4-OXAZÉPINES EN TANT QU'INHIBITEURS DE BACE1 ET/OU BACE2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012110459A1

  公开（公告）日：2012-08-23

  This invention relates to compounds of the formula wherein and R1 to R3 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.

  这项发明涉及以下式中的化合物，其中R1至R3如下所述，或其药学上可接受的盐。这些化合物是BACE1和/或BACE2抑制剂，可用作治疗和/或预防治疗阿尔茨海默病、糖尿病，特别是2型糖尿病，以及其他代谢性疾病的药物。
• FUSED AMINODIHYDROTHIAZINE DERIVATIVES
  申请人：SUZUKI Yuichi

  公开号：US20090209755A1

  公开（公告）日：2009-08-20

  A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C 6-14 aryl group or the like, L is —NR e CO— or the like (wherein R e is a hydrogen atom or the like), Ring B is a C 6-14 aryl group or the like, X is a C 1-3 alkylene group or the like, Y is a single bond or the like, Z is a C 1-3 alkylene group or the like, R 1 and R 2 are each independently a hydrogen atom or the like, and R 3 , R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

  一个由以下通用公式表示的化合物：或其药用可接受的盐或其溶剂化物，其中环A是C6-14芳基或类似物，L是—NReCO—或类似物（其中Re是氢原子或类似物），环B是C6-14芳基或类似物，X是C1-3烷基烯基或类似物，Y是单键或类似物，Z是C1-3烷基烯基或类似物，R1和R2各自独立地是氢原子或类似物，而R3、R4、R5和R6各自独立地是氢原子、卤原子或类似物，具有Aβ产生抑制作用或BACE1抑制作用，并且可用作由Aβ引起的以阿尔茨海默型痴呆为特征的神经退行性疾病的预防或治疗剂。
• 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS
  申请人：Hilpert Hans

  公开号：US20130040936A1

  公开（公告）日：2013-02-14

  This invention relates to compounds of the formula wherein and R 1 to R 3 are as described herein, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as pharmaceuticals for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.

  本发明涉及公式中的化合物，其中R1至R3如本文所述，或其药用可接受的盐。这些化合物是BACE1和/或BACE2抑制剂，可用作药物治疗和/或预防治疗阿尔茨海默病、糖尿病，特别是2型糖尿病，以及其他代谢性疾病。
• 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
  申请人：Hilpert Hans

  公开号：US08815841B2

  公开（公告）日：2014-08-26

  This invention relates to compounds of the formula wherein and R1 to R3 are as described herein, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as pharmaceuticals for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.

  本发明涉及式中的化合物，其中R1至R3如本文所述，或其药学上可接受的盐。这些化合物是BACE1和/或BACE2抑制剂，可用作药物治疗和/或预防治疗阿尔茨海默病、糖尿病，特别是2型糖尿病和其他代谢性疾病。
• 1,4 OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20140323469A1

  公开（公告）日：2014-10-30

  This invention relates to compounds of the formula wherein and R 1 to R 3 are as described herein, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as pharmaceuticals for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.

  本发明涉及以下式子的化合物 其中R1到R3如本文所述，或其药学上可接受的盐。这些化合物是BACE1和/或BACE2抑制剂，可用作药物治疗和/或预防治疗阿尔茨海默病、糖尿病，尤其是2型糖尿病和其他代谢性疾病。